BioSpace News Archive

Technology enabled, data-driven Managed Access company RareiTi is delighted to announce the appointment of Dr. Olivia Kessel as Chief Medical Officer.

Twist Bioscience Corporation (Nasdaq: TWST) and Beyond Earth, an artist collective, today announced a project to store high-resolution artworks in DNA to be launched to low Earth orbit and the Moon. Beyond Earth artists that will contribute work to the project include: Elena Soterakis, New York, NY; Richelle Gribble, Los Angeles, CA; and Yoko Shimizu, Linz, Austria and Tokyo, Japan.

NexImmune, a clinical-stage biotechnology company developing unique non-genetically-engineered T cell immunotherapies, announced today that it has signed a research initiative related to its AIM nanoparticle technology with City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases. City of Hope is a participating clinical site in the ongoing Phase 1/2 study of NEXI-001

Covetrus (NASDAQ: CVET), a global leader in animal-health technology and services, announced today that it will release third quarter 2020 results after the market close on Tuesday, November 10, 2020.

With nearly 70% turning to their pets to de-stress and 64% willing to have a conversation with someone they disagree with politically if that person is a pet owner, Banfield Pet Hospital® survey suggests growing power pets have in bringing people together

BioStem Technologies, Inc. (OTC PINK: BSEM) (“BioStem” or the “Company”), a leading life sciences company specializing in perinatal tissue allografts for use in regenerative therapies, today announced the launch of AEON™, the 6th and newest addition to the Company’s perinatal tissue allograft platform.

Safety and efficacy data from Phase II clinical trial of nomacopan in adults with mild to moderate BP The Phase II data was the basis for the agreement of the FDA and the EMA that Akari may proceed to a Phase III randomised placebo - controlled study usin g nomacopan for treatment of BP Phase III study in both the U.S. and Europe expected to begin in H1 2021 Nomacopan has been granted orphan drug designation for treatment of BP in the U.S. and Europe

Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, announced updates on its Phase 3 clinical development program of NVX-CoV2373, its COVID-19 vaccine candidate. NVX‑CoV2373 is a stable, prefusion protein made using Novavax’ nanoparticle technology and includes Novavax’ proprietary Matrix‑M™ adjuvant.

RetinalGeniX™ Technologies, Inc. www.retinalgenix.com announced today the launch of its RetinalCam™ Home Monitoring & Physician Alert System

Entos is working with Applied Pharmaceutical Innovation (API) to ensure secure supply of inputs for its vaccine production and the ability to expand its Edmonton facilities. API has been providing Entos with enhanced capacity to support its growing team.